Also found in: Dictionary.


trademark for a preparation of cefaclor, a broad-spectrum cephalosporinantibiotic.


(sef-a-klor) ,


(trade name),


(trade name)


Therapeutic: anti infectives
Pharmacologic: second generation cephalosporins
Pregnancy Category: B


Treatment of the following infections caused by susceptible organisms:
  • Respiratory tract infections,
  • Skin and skin structure infections,
  • Urinary tract infections,
  • Otitis media.


Binds to bacterial cell wall membrane, causing cell death.

Therapeutic effects

Bactericidal action against susceptible bacteria.
Similar to that of first-generation cephalosporins but has increased activity against several other gram-negative pathogens including:
  • Haemophilus influenzae,
  • Escherichia coli,
  • Klebsiella pneumoniae,
  • Proteus mirabilis.
Not active against methicillin-resistant staphylococci or enterococci.


Absorption: Well absorbed after oral administration.
Distribution: Widely distributed. Penetration into CSF is poor. Crosses the placenta and enters breast milk in low concentrations.
Metabolism and Excretion: Excreted primarily unchanged by the kidneys.
Half-life: 30–60 min (increased in renal impairment).

Time/action profile

POrapid30–60 min6–12 hr
PO-CDunknownunknown12 hr


Contraindicated in: Hypersensitivity to cephalosporins; Serious hypersensitivity to penicillins.
Use Cautiously in: Renal impairment ; History of GI disease, especially colitis; Pregnancy and lactation (has been used safely).

Adverse Reactions/Side Effects

Central nervous system

  • seizures (very high doses) (life-threatening)


  • pseudomembranous colitis (life-threatening)
  • diarrhea
  • nausea
  • vomiting


  • rashes
  • urticaria


  • agranulocytosis
  • bleeding
  • eosinophilia
  • hemolytic anemia
  • neutropenia


  • allergic reactions including anaphylaxis and serum sickness (life-threatening)
  • superinfection


Drug-Drug interaction

Probenecid decreases excretion and increases blood levels.Antacids decrease absorption.


Oral (Adults) 250–500 mg q 8 hr or 375–500 mg q 12 hr as extended-release tablets.
Oral (Children >1 mo) 6.7–13.4 mg/kg q 8 hr or 10–20 mg/kg q 12 hr (up to 1 g/day).

Availability (generic available)

Capsules: 250 mg, 500 mg
Extended-release tablets (CD): 375 mg, 500 mg
Chewable tabletfruity: 125 mg, 187 mg, 250 mg, 375 mg
Oral suspensionstrawberry: 125 mg/5 mL, 187 mg/5 mL, 250 mg/5 mL, 375 mg/5 mL

Nursing implications

Nursing assessment

  • Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and during therapy.
  • Before initiating therapy, obtain a history to determine previous use of and reactions to penicillins or cephalosporins. Persons with a negative history of penicillin sensitivity may still have an allergic response.
  • Obtain specimens for culture and sensitivity before initiating therapy. First dose may be given before receiving results.
  • Observe patient for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing). Discontinue the drug and notify the physician or other health care professional immediately if these symptoms occur. Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction.
  • Lab Test Considerations: May cause positive results for Coombs' test.
    • May cause increased serum AST, ALT, alkaline phosphatase, bilirubin, LDH, BUN, and creatinine.
    • May rarely cause neutropenia, agranulocytosis, and eosinophilia.

Potential Nursing Diagnoses

Risk for infection (Indications,  Side Effects)
Diarrhea (Adverse Reactions)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Oral: Administer around the clock. Chewable tablets, capsules, or suspension may be administered on full or empty stomach. Administration with food may minimize GI irritation. Extended-release tablets should be taken with food. Shake oral suspension well before administering. Suspension is stable for 14 days after reconstitution if refrigerated.
    • Do not administer within 1 hr of taking antacids.
    • Do not crush, break, or chew extended-release tablets.

Patient/Family Teaching

  • Instruct patient to take medication around the clock at evenly spaced times and to finish the medication completely, even if feeling better. Missed doses should be taken as soon as possible unless almost time for next dose; do not double doses. Instruct patient to use calibrated measuring device with suspension. Advise patient that sharing of this medication may be dangerous.
  • Advise patient to report signs of superinfection (furry overgrowth on the tongue, vaginal itching or discharge, loose or foul-smelling stools) and allergy.
  • Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional.

Evaluation/Desired Outcomes

  • Resolution of signs and symptoms of infection. Length of time for complete resolution depends on the organism and site of infection.


a trademark for a cephalosporin antibiotic (cefaclor).
References in periodicals archive ?
In various press releases, Dura made statements to the effect that Spiros was on track for FDA approval and that its respiratory antibiotic Ceclor CD was experiencing strong sales and had increased its market share significantly.
Second-generation cephalosporin antibiotics on the approved list include Cefaclor, Cefaclor ER, Ceftin, Cefzil, Ceptaz, and Rocephin, while Ceclor CD, Cedar, Cefotan, and Lorabid must receive authorization.
At its 140-acre, 85-building site, Clinton Laboratories makes antibiotics such as Ceclor, Keftabl and Lorabid, as well as animal-health products such as Montban, Rumensin and Tylan.
Cefaclor Extended Release Tablets are the AB-rated generic equivalent of Eli Lilly's Ceclor CD, marketed by Elan Corporation.
The Complaint alleges that defendants made false and misleading statements about Dura's supposedly well-trained and highly effective sales force, strong sales of Dura's Ceclor CD, Keftab, Nasarel/Nasalide, Rondec and Dura-Vent products, and the successful development of its new Spiros drug delivery system while forecasting its commercial release in late 1998/early 1999 and $150 million in sales by 2000, strong growth in Ceclor CD sales in 1998 to $50-55 million, 1998 earnings per share ("EPS") of $1.
The carrying values of Ceclor CD(TM) and Naprelan(TM) were written-down by $84 million and $81 million, respectively, reflecting impairments due to reduced revenues from these products.
Most contacts involved contracting issues for the antibiotic cefaclor, the generic version of Ceclor.
The drugs are Keftab(R), with projected sales of about US$15 million this year, and Ceclor CD(R), which the Food and Drug Administration recently approved for sale and which Dura plans to launch soon in conjunction with a significant sales force expansion.
Dura will begin promoting Keftab to physicians immediately after the transaction closes and will launch and promote Ceclor CD, which was cleared for marketing by the U.
Market share for Ceclor CD in the second and third generation cephalosporin market increased more than one full share point during the quarter and as of October 1, 1999 was at an all-time high of 8.
Axid (nizatidine, Lilly) Ceclor (cefaclor, Lilly) Gemzar (gemcitabine hydrochloride, Lilly) Humalog (insulin lispro, Lilly) Humulin (human insulin of recombinant DNA origin, Lilly) Humatrope (somatropin of recombinant DNA origin, Lilly) Keftab (cephalexin hydrochloride, Dista) Keflex (cephalexin, Dista) Lorabid (loracarbef, Lilly) Prozac (fluoxetine hydrochloride, Dista) ReoPro (abciximab), Lilly Vancocin (vancomycin hydrochloride, Lilly)